Skip to content

Feasibility of Parathyroidectomy With Exploration of 4 Parathyroid Glands in Outpatients

Feasibility of Parathyroidectomy With Exploration of 4 Parathyroid Glands in Outpatients, for Treatment of Primary Hyperparathyroidism

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03732157
Acronym
PARAMBU
Enrollment
140
Registered
2018-11-06
Start date
2018-11-30
Completion date
2019-07-31
Last updated
2018-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Hyperparathyroidism

Keywords

Primary Hyperparathyroidism, Parathyroidectomy, Outpatient management

Brief summary

The development of outpatient surgery has become a national priority, with the objective of an ambulatory surgery rate of around 50% in 2016, whereas this rate reached only 37.7% in 2010. In the context of the management of primary hyperparathyroidism, there are two possible approaches. The first, which is commonly performed on an outpatient basis, consists in approaching only the pathological gland, if it was first identified by scintigraphy and ultrasound (which is the case in one patient in two), without exploring the others parathyroid glands. The reference technique consists in exploring the 4 parathyroid sites by transverse cervicotomy. Although more invasive, it minimizes the risk of failure due to the lack of knowledge of multi-glandular forms of the disease (15 to 20%), whose preoperative diagnosis is difficult. This reference technique is poorly performed on an outpatient basis while it lends itself to this type of management because of the superficial character of the operative site, a short operating time, moderate postoperative pain, rapid return oral nutrition and exceptional and early serious complications (delay \<24 h for cervical hematoma, \<24 h for hypocalcemia and immediate diagnosis of recurrent palsy). In this study, the investigators hypothesize that parathyroidectomy with 4-gland parathyroid exploration is feasible by ensuring patient safety. The investigators also believe that outpatient management will not lead to any difference after 3-month surgery, but will reduce hospitalization costs while increasing patient satisfaction with conventional care. To do so, the investigators carried out an observational cohort study of patients with an indication of parathyroidectomy wo will undergo outpatient management or conventional management (stay overnight in hospital) to inform all of these data.

Interventions

PROCEDUREoutpatient management of parathyroidectomy

The patient is discharged from hospital the same day of the parathyroidectomy intervention instead of conventional management (stay overnight in hospital)

PROCEDUREconventional management of parathyroidectomy

The patient stays overnight in hospital after intervention

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Patients \> 18 years old * Diagnosis of primary hyperparathyroidism (inappropriate parathyroid hormone secretion compared with calcemia) * Surgical indication of parathyroidectomy with possible management outpatient or conventional hospitalization (choice of mode of care by the surgeon, after consultation with the patient)

Exclusion criteria

* Non-eligibility for outpatient surgery for general medical reasons (ASA score), determined during the consultation of preoperative anesthesia * Preoperative hypercalcemia\> 3 mmol / L (due to the high risk of postoperative hypocalcemia) * History of cervicotomy for thyroidectomy or failure of parathyroid surgery * Treatment of primary hyperparathyroidism with elective surgical approach * Person under guardianship and curatorship

Design outcomes

Primary

MeasureTime frameDescription
Proportion of conversion or readmission to conventional hospitalizationwithin 8 days postoperativelyThe primary endpoint will be assessed for patients receiving outpatient management. Proportion of patients who could not discharged from hospital the same day of surgery as originally scheduled or being readmitted to conventional hospitalization within 8 days post operatively.

Secondary

MeasureTime frameDescription
Proportion of patients with breathing difficulty.at day 1 post operativelyDyspnea will be evaluated using the New York Heart Association (NYHA) Functional Classification. The stage of dyspnea is classified in four categories based on how much patients are limited during physical activity. Breathing difficulty will be defined by a stage of 3 on the NYHA scale.
Proportion of patients with compressive cervical hematomaat day 0 post operativelyclinical evaluation based on the occurrence of a cervical collection that can obstruct the upper aero-digestive tract (NYHA scale dyspnea)
Proportion of patients with hypocalcemiaat day 1 post operativelyHypocalcemia will be defined as calcemia lower than 2 mmol/L or 80 mg/L
Postoperative pain evaluated using visual analogue scale (VAS)at day 0 post operativelyPain will be evaluated using visual analogue scale (VAS) . VAS score ranges from 0 to 10. A high VAS score represents a high level of pain while a low VAS score represents a low level of pain.
Patients' satisfaction regarding his/her care evaluated using visual analogue scale (VAS)at day 0 post operativelyPatients' satisfaction evaluated using visual analogue scale (VAS). VAS score ranges from 0 to 10. A high VAS score represents a high level of satisfaction while a low VAS score represents a low level of satisfaction.
Total cost of mode of careat 3 months post operativelyTotal cost of hospital surgery stay and hospital readmission at 3 months
Proportion of patients with recurrent nerve paralysisat day 0 post operativelyClinical evaluation based on the occurrence of voice modification with swallowing disorder

Contacts

Primary ContactPierre CATTAN, Pr
pierre.cattan@aphp.fr0142499381
Backup ContactMatthieu RESCHE-RIGON, Pr
matthieu.resche-rigon@univ-paris-diderot.fr0142499742

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026